Pyrilutamide is officially available for purchase, and users suggest Fluridil as an alternative topical anti-androgen. Some users report positive results with pyrilutamide from Koshine.
RU58841 is not recommended for use around children due to potential exposure risks. Alternatives like CB-03-01 might be considered, but further research is advised.
The user is using 5% topical minoxidil twice daily and 1.25 mg oral finasteride for hair thinning at the temples. They are considering switching to once-daily minoxidil due to scalp flakiness and future time constraints.
A user started taking 0.5 mg of finasteride daily and noticed watery semen, questioning if it's normal or if they should adjust the dosage. Another user suggested it might indicate reduced fertility and may not improve.
The user is experimenting with topical melatonin for hair loss by dissolving melatonin tablets in a solution, but is having trouble with dissolution and is curious about others' methods of application and any effects on energy levels. They mention considering mixing with minoxidil but have not done so, and suggest that melatonin is best used at night.
The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.
The conversation discusses the use of creatine while on finasteride and/or dutasteride for hair loss. Opinions vary, with some users reporting no issues and others experiencing accelerated hair loss, suggesting effects are individual.
The user is currently using alfatradiol and fluridil for hair loss and is considering adding low-dose topical finasteride but is concerned about potential side effects due to past mental health issues. They are seeking others' experiences with these treatments and their effectiveness.
The conversation is about when the phase 3 results for pyrilutamide, a potential hair loss treatment, will be released. There was a letter about the study a month ago, but the actual results were not included.
The conversation discusses concerns about Dr. Rassman's topical Finasteride, specifically whether it is liposomal or glycol-based. Dr. Rassman insists on providing the correct liposomal formulation and urges patients to contact him if they receive the wrong product.